查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1933327

全球心房顫動市場：市場規模、佔有率、成長率、產業分析、依類型、應用和地區劃分的分析及預測（2026-2034 年）

Atrial Fibrillation Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 143 Pages | 商品交期: 請詢問到貨日

價格

心房顫動市場成長因素

受心血管疾病盛行率上升、人口老化以及藥物治療不斷進步的推動，全球心房顫動市場正經歷穩定成長。心房顫動（Afib）是一種以不規則、通常快速的心律為特徵的心律不整，會顯著增加中風、心臟衰竭和其他心血管併發症的風險。此疾病與高血壓、心肌病變、肥胖、吸菸和老化密切相關，使其成為全球日益嚴重的公共衛生問題。

2025年全球心房顫動市場價值為172.4億美元。預計到2026年，該市場將成長至179.9億美元，到2034年將達到257.5億美元，2026年至2034年的複合年增長率為4.59%。市場的持續擴張反映了對有效長期治療方案的需求不斷增長，以及患者獲得治療選擇的機會日益增加。

市場驅動因素

心血管疾病負擔日益加重是推動市場成長的關鍵因素之一。根據世界衛生組織（WHO）統計，到2023年，全球將有12.8億成年人患有高血壓，而高血壓是心房顫動的主要危險因子。高血壓引起的心臟結構和功能改變會顯著增加心律不整的發生率。

此外，老年人口的快速成長也導致心房顫動盛行率上升。根據聯合國2023年的報告，預計到2050年，65歲及以上人口將達到16億，這將導致對心房顫動治療的需求增加。發展中地區人們對心房顫動的認識提高、早期診斷和醫療保健服務的普及也促進了市場成長。

市場趨勢

影響市場的關鍵趨勢是，人們越來越關注新藥研發，特別是單株抗體和因子XI/因子XIa抑制劑。大型製藥公司正在大力投資創新療法，以降低出血風險並維持抗凝血療效。例如，Anthos Therapeutics公司正在開發avelaccimab，這是一種全人源單株抗體，可在不損害止血功能的情況下提供抗凝血作用。

監管機構也正在透過授予快速審批通道和特殊認定來支持創新，加速新型療法的臨床開發和市場准入。預計這一趨勢將在預測期內顯著改善治療效果並擴大治療選擇。

新冠疫情的影響

在新冠疫情期間，心房顫動市場成長放緩，主要原因是供應鏈中斷、診所暫時關閉、擇期手術減少。根據2022年發表在 "臨床醫學雜誌" 上的一篇論文，導管消融術和左心耳封堵術在疫情期間顯著減少。

然而，藥物治療仍然是首選的治療方法，支撐了穩定的藥物需求。隨著疫情後的復甦，診斷數量和治療啟動數量均恢復，市場也恢復正常的成長水準。

限制因子

儘管成長前景光明，市場仍面臨諸多挑戰，包括產品召回事件增多以及替代療法的出現。因生產缺陷、標籤錯誤和品質問題導致的產品召回可能會對品牌信任度和患者依從性產生負面影響。例如，2023年多非利特和地高辛的回想引發了安全擔憂，暫時削弱了市場信心，並可能導致患者轉向非藥物療法。

細分市場分析

依藥物類別劃分，市場分為抗凝血劑和抗心律不整藥物。抗凝血劑市場在強有力的臨床指南和直接口服抗凝血劑 (DOAC) 的廣泛應用推動下，預計將在 2026 年佔 78.92% 的市場佔有率。

依給藥途徑劃分，口服給藥途徑預計將在 2026 年佔 84.98% 的市場佔有率。這主要得益於口服給藥的便捷性、更高的患者依從性以及多種口服藥物的選擇。

依分銷管道劃分，零售藥局預計在 2026 年佔 48.03% 的市場佔有率。這主要得益於零售藥局的便利性、不斷擴大的藥局網路以及成本優勢。

區域洞察

北美地區預計將在 2025 年引領心房顫動市場，佔 38.33% 的市佔率（價值 66.1 億美元）。該地區的優勢包括高疾病發生率、強有力的監管支持和人口老化。預計到2026年，美國市場規模將達到61.4億美元。

歐洲佔第二大市場佔有率，這主要得益於心血管疾病發生率的上升和強勁的研發投入。亞太地區預計將實現最快成長，這得益於公眾意識的提高、醫療基礎設施的擴展以及人口的快速老化。預計到2026年，日本、中國和印度的市場規模將分別達到6.9億美元、8.9億美元和6.4億美元。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：關鍵考慮因素

  • 主要地區心律不整盛行率/發生率（2024/2025）
  • 主要產業趨勢：併購、業務合作
  • 主要公司新產品發布
  • COVID-19 對心房顫動市場的影響

第五章：全球心房顫動市場分析：洞察與預測（2021-2034）

  • 市場分析、洞察與預測：依藥物類別劃分
    • 抗凝血藥
    • 抗心律不整藥
  • 市場分析、洞察與預測：依給藥途徑劃分
    • 口服
    • 靜脈注射
    • 其他
  • 市場分析、洞察與預測：依通路劃分
    • 醫院藥房
    • 線上藥房
    • 零售藥房
  • 市場分析、洞察與預測：依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

章節第六章 北美心房顫動市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第七章：歐洲心房顫動市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪的納維亞
    • 歐洲其他地區

第八章 亞太地區心房顫動市場分析、洞察與預測（2021-2034）

  • 依國家/地區劃分
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章：拉丁美洲心房顫動市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第十章：中東與非洲心房顫動市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • 海灣合作委員會（GCC）國家
    • 南非
    • 其他中東國家東非/非洲

第11章 競爭分析

  • 全球市場佔有率分析(2025年)
  • 企業簡介
    • Bristol-Myers Squibb Company
    • Sanofi
    • Eisai Co., Ltd.
    • Johnson &Johnson
    • Daiichi Sankyo, Inc.
    • Par Pharmaceutical
    • Bayer AG
    • Pfizer Inc.
Product Code: FBI108921

Growth Factors of atrial fibrillation Market

The global atrial fibrillation market is experiencing steady growth, driven by the rising prevalence of cardiovascular disorders, increasing geriatric population, and continuous advancements in pharmacological therapies. Atrial fibrillation (Afib) is a cardiac arrhythmia characterized by irregular and often rapid heart rhythm, which significantly increases the risk of stroke, heart failure, and other cardiovascular complications. The condition is commonly associated with hypertension, cardiomyopathy, obesity, smoking, and advancing age, making it a growing public health concern worldwide.

In 2025, the global atrial fibrillation market size was valued at USD 17.24 billion. The market is projected to grow to USD 17.99 billion in 2026 and further reach USD 25.75 billion by 2034, exhibiting a CAGR of 4.59% from 2026 to 2034. The consistent expansion of the market reflects the increasing demand for effective long-term management therapies and improved patient access to treatment options.

Market Drivers

The rising burden of cardiovascular diseases is one of the primary factors driving market growth. According to the World Health Organization (WHO), 1.28 billion adults globally were suffering from hypertension in 2023, a key risk factor for atrial fibrillation. Structural and functional changes in the heart caused by hypertension significantly increase the likelihood of arrhythmias.

Additionally, the rapidly growing geriatric population is contributing to the rising prevalence of Afib. As per the United Nations 2023 report, the global population aged 65 years and above is projected to reach 1.6 billion by 2050, leading to higher demand for atrial fibrillation therapies. Increasing awareness, early diagnosis, and expanding access to healthcare services in developing regions are further supporting market growth.

Market Trends

A major trend shaping the market is the increasing focus on novel drug development, particularly monoclonal antibodies and Factor XI/XIa inhibitors. Key pharmaceutical players are investing heavily in innovative therapies aimed at reducing bleeding risks while maintaining anticoagulant efficacy. For instance, Anthos Therapeutics is developing abelacimab, a fully human monoclonal antibody designed to provide hemostasis-sparing anticoagulation.

Regulatory bodies are also supporting innovation by granting fast-track approvals and special designations, enabling faster clinical development and market entry of novel therapies. This trend is expected to significantly improve treatment outcomes and expand therapeutic options during the forecast period.

COVID-19 Impact

The atrial fibrillation market experienced slow growth during the COVID-19 pandemic, mainly due to supply chain disruptions, temporary clinic closures, and reduced elective procedures. According to a 2022 publication in the Journal of Clinical Medicine, there was a notable decline in catheter ablation and left atrial appendage occlusion procedures during the pandemic.

However, pharmacotherapy remained the preferred treatment approach, supporting steady drug demand. Post-pandemic recovery led to a rebound in diagnoses and treatment initiation, allowing the market to return to normal growth levels.

Restraining Factors

Despite positive growth prospects, the market faces challenges from rising product recalls and the availability of alternative treatment approaches. Product recalls due to manufacturing defects, labeling errors, and quality concerns can negatively impact brand trust and patient adherence. For example, recalls of drugs such as dofetilide and digoxin in 2023 raised safety concerns and temporarily affected market confidence, potentially shifting patient preference toward non-pharmacological interventions.

Segmentation Analysis

By drug class, the market is segmented into anticoagulants and antiarrhythmic drugs. The anticoagulants segment dominated the market, accounting for 78.92% share in 2026, driven by strong clinical guidelines and widespread adoption of direct oral anticoagulants (DOACs).

By route of administration, the oral segment led the market with an 84.98% share in 2026, owing to ease of use, better patient compliance, and a wide range of orally available drugs.

By distribution channel, retail pharmacies dominated with a 48.03% share in 2026, supported by consumer convenience, expanding pharmacy networks, and cost advantages.

Regional Insights

North America dominated the atrial fibrillation market in 2025, accounting for 38.33% market share and valued at USD 6.61 billion. The region benefits from a high disease prevalence, strong regulatory support, and a large elderly population. The U.S. market is projected to reach USD 6.14 billion by 2026.

Europe held the second-largest share, driven by increasing cardiovascular disease prevalence and strong R&D investments. Asia Pacific is projected to witness the fastest growth due to rising awareness, expanding healthcare infrastructure, and a rapidly aging population. By 2026, Japan, China, and India are projected to reach USD 0.69 billion, USD 0.89 billion, and USD 0.64 billion, respectively.

Competitive Landscape

The global market is semi-consolidated, with key players such as Bayer AG, Bristol-Myers Squibb, Daiichi Sankyo, Sanofi, Pfizer, and Johnson & Johnson. These companies focus on product innovation, clinical trials, geographic expansion, and strategic collaborations to strengthen their market positions.

Conclusion

The global atrial fibrillation market is poised for steady growth, supported by the rising prevalence of cardiovascular disorders, an expanding geriatric population, and continuous advancements in drug development. Valued at USD 17.24 billion in 2025, the market is expected to grow to USD 25.75 billion by 2034. While challenges such as product recalls and alternative treatment options persist, ongoing innovation, supportive regulatory frameworks, and increasing global awareness are expected to sustain market expansion and create long-term growth opportunities.

Segmentation By Drug Class

  • Anticoagulants
  • Antiarrhythmic Drugs

By Route of Administration

  • Oral
  • Intravenous
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

By Region

  • North America (By Drug Class, Route of Administration, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
    • China
    • India
    • Japan
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence/Incidence of Arrhythmia, Key Region, 2024/2025
  • 4.2. Key Industry Developments - Mergers, Partnerships, Acquisitions
  • 4.3. New Product Launches by Key Players
  • 4.4. Impact of COVID-19 on Atrial Fibrillation Market

5. Global Atrial Fibrillation Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug Class
    • 5.1.1. Anticoagulants
    • 5.1.2. Anti-arrhythmic Drugs
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Oral
    • 5.2.2. Intravenous
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospital Pharmacies
    • 5.3.2. Online Pharmacies
    • 5.3.3. Retail Pharmacies
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Atrial Fibrillation Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug Class
    • 6.1.1. Anticoagulants
    • 6.1.2. Anti-arrhythmic Drugs
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Oral
    • 6.2.2. Intravenous
    • 6.2.3. Others
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospital Pharmacies
    • 6.3.2. Online Pharmacies
    • 6.3.3. Retail Pharmacies
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
      • 6.4.1.1. By Drug Class
    • 6.4.2. Canada
      • 6.4.2.1. By Drug Class

7. Europe Atrial Fibrillation Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug Class
    • 7.1.1. Anticoagulants
    • 7.1.2. Anti-arrhythmic Drugs
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Oral
    • 7.2.2. Intravenous
    • 7.2.3. Others
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Online Pharmacies
    • 7.3.3. Retail Pharmacies
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 7.4.1. Germany
      • 7.4.1.1. By Drug Class
    • 7.4.2. U.K.
      • 7.4.2.1. By Drug Class
    • 7.4.3. France
      • 7.4.3.1. By Drug Class
    • 7.4.4. Spain
      • 7.4.4.1. By Drug Class
    • 7.4.5. Italy
      • 7.4.5.1. By Drug Class
    • 7.4.6. Scandinavia
      • 7.4.6.1. By Drug Class
    • 7.4.7. Rest of Europe
      • 7.4.7.1. By Drug Class

8. Asia Pacific Atrial Fibrillation Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug Class
    • 8.1.1. Anticoagulants
    • 8.1.2. Anti-arrhythmic Drugs
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Oral
    • 8.2.2. Intravenous
    • 8.2.3. Others
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Online Pharmacies
    • 8.3.3. Retail Pharmacies
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 8.4.1. Japan
      • 8.4.1.1. By Drug Class
    • 8.4.2. China
      • 8.4.2.1. By Drug Class
    • 8.4.3. India
      • 8.4.3.1. By Drug Class
    • 8.4.4. Australia
      • 8.4.4.1. By Drug Class
    • 8.4.5. Southeast Asia
      • 8.4.5.1. By Drug Class
    • 8.4.6. Rest of Asia Pacific
      • 8.4.6.1. By Drug Class

9. Latin America Atrial Fibrillation Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug Class
    • 9.1.1. Anticoagulants
    • 9.1.2. Anti-arrhythmic Drugs
  • 9.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.2.1. Oral
    • 9.2.2. Intravenous
    • 9.2.3. Others
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Online Pharmacies
    • 9.3.3. Retail Pharmacies
  • 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 9.4.1. Brazil
      • 9.4.1.1. By Drug Class
    • 9.4.2. Mexico
      • 9.4.2.1. By Drug Class
    • 9.4.3. Rest of Latin America
      • 9.4.3.1. By Drug Class

10. Middle East & Africa Atrial Fibrillation Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Drug Class
    • 10.1.1. Anticoagulants
    • 10.1.2. Anti-arrhythmic Drugs
  • 10.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.2.1. Oral
    • 10.2.2. Intravenous
    • 10.2.3. Others
  • 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.3.1. Hospital Pharmacies
    • 10.3.2. Online Pharmacies
    • 10.3.3. Retail Pharmacies
  • 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 10.4.1. GCC
      • 10.4.1.1. By Drug Class
    • 10.4.2. South Africa
      • 10.4.2.1. By Drug Class
    • 10.4.3. Rest of Middle East & Africa
      • 10.4.3.1. By Drug Class

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Bristol-Myers Squibb Company
      • 11.2.1.1. Overview
      • 11.2.1.2. Product
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. financials (Based on Availability)
    • 11.2.2. Sanofi
      • 11.2.2.1. Overview
      • 11.2.2.2. Product
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. financials (Based on Availability)
    • 11.2.3. Eisai Co., Ltd.
      • 11.2.3.1. Overview
      • 11.2.3.2. Product
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. financials (Based on Availability)
    • 11.2.4. Johnson & Johnson
      • 11.2.4.1. Overview
      • 11.2.4.2. Product
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. financials (Based on Availability)
    • 11.2.5. Daiichi Sankyo, Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Product
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. financials (Based on Availability)
    • 11.2.6. Par Pharmaceutical
      • 11.2.6.1. Overview
      • 11.2.6.2. Product
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. financials (Based on Availability)
    • 11.2.7. Bayer AG
      • 11.2.7.1. Overview
      • 11.2.7.2. Product
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. financials (Based on Availability)
    • 11.2.8. Pfizer Inc.
      • 11.2.8.1. Overview
      • 11.2.8.2. Product
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. financials (Based on Availability)

List of Tables

  • Table 1: Global Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 2: Global Atrial Fibrillation Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 3: Global Atrial Fibrillation Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 4: Global Atrial Fibrillation Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 5: North America Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 6: North America Atrial Fibrillation Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 7: North America Atrial Fibrillation Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 8: North America Atrial Fibrillation Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 9: U.S. Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 10: Canada Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 11: Europe Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 12: Europe Atrial Fibrillation Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 13: Europe Atrial Fibrillation Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 14: Europe Atrial Fibrillation Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 15: Germany Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 16: U.K. Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 17: France Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 18: Italy Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 19: Spain Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 20: Scandinavia Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 21: Rest of Europe Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 22: Asia Pacific Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 23: Asia Pacific Atrial Fibrillation Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 24: Asia Pacific Atrial Fibrillation Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 25: Asia Pacific Atrial Fibrillation Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 26: Japan Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 27: India Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 28: China Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 29: Australia Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 30: Southeast Asia Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 31: Rest of Asia Pacific Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 32: Latin America Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 33: Latin America Atrial Fibrillation Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 34: Latin America Atrial Fibrillation Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 35: Latin America Atrial Fibrillation Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 36: Brazil Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 37: Mexico Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 38: Rest of Latin America Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 39: Middle East & Africa Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 40: Middle East & Africa Atrial Fibrillation Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 41: Middle East & Africa Atrial Fibrillation Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 42: Middle East & Africa Atrial Fibrillation Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 43: GCC Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 44: South Africa Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 45: Rest of Middle East & Africa Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034

List of Figures

  • Figure 1: Global Atrial Fibrillation Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Atrial Fibrillation Market Value Share (%), by Drug Class, 2025 & 2034
  • Figure 3: Global Atrial Fibrillation Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 4: Global Atrial Fibrillation Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 5: Global Atrial Fibrillation Market Value Share (%), by Region, 2025 & 2034
  • Figure 6: North America Atrial Fibrillation Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 7: North America Atrial Fibrillation Market Value Share (%), by Drug Class, 2025
  • Figure 8: North America Atrial Fibrillation Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 9: North America Atrial Fibrillation Market Value Share (%), by Route of Administration, 2025
  • Figure 10: North America Atrial Fibrillation Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 11: North America Atrial Fibrillation Market Value Share (%), by Distribution Channel, 2025
  • Figure 12: North America Atrial Fibrillation Market Value (USD billion), By Country, 2025 & 2034
  • Figure 13: North America Atrial Fibrillation Market Value Share (%), By Country, 2025
  • Figure 14: Europe Atrial Fibrillation Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 15: Europe Atrial Fibrillation Market Value Share (%), by Drug Class, 2025
  • Figure 16: Europe Atrial Fibrillation Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 17: Europe Atrial Fibrillation Market Value Share (%), by Route of Administration, 2025
  • Figure 18: Europe Atrial Fibrillation Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 19: Europe Atrial Fibrillation Market Value Share (%), by Distribution Channel, 2025
  • Figure 20: Europe Atrial Fibrillation Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Atrial Fibrillation Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Atrial Fibrillation Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 23: Asia Pacific Atrial Fibrillation Market Value Share (%), by Drug Class y, 2025
  • Figure 24: Asia Pacific Atrial Fibrillation Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 25: Asia Pacific Atrial Fibrillation Market Value Share (%), by Route of Administration, 2025
  • Figure 26: Asia Pacific Atrial Fibrillation Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 27: Asia Pacific Atrial Fibrillation Market Value Share (%), by Distribution Channel, 2025
  • Figure 28: Asia Pacific Atrial Fibrillation Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Atrial Fibrillation Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 30: Latin America Atrial Fibrillation Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 31: Latin America Atrial Fibrillation Market Value Share (%), by Drug Class, 2025
  • Figure 32: Latin America Atrial Fibrillation Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 33: Latin America Atrial Fibrillation Market Value Share (%), by Route of Administration, 2025
  • Figure 34: Latin America Atrial Fibrillation Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 35: Latin America Atrial Fibrillation Market Value Share (%), by Distribution Channel, 2025
  • Figure 36: Latin America Atrial Fibrillation Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 37: Latin America Atrial Fibrillation Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 38: Middle East & Africa Atrial Fibrillation Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 39: Middle East & Africa Atrial Fibrillation Market Value Share (%), by Drug Class, 2025
  • Figure 40: Middle East & Africa Atrial Fibrillation Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 41: Middle East & Africa Atrial Fibrillation Market Value Share (%), by Route of Administration, 2025
  • Figure 42: Middle East & Africa Atrial Fibrillation Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 43: Middle East & Africa Atrial Fibrillation Market Value Share (%), by Distribution Channel, 2025
  • Figure 44: Middle East & Africa Atrial Fibrillation Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 45: Middle East & Africa Atrial Fibrillation Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 46: Global Atrial Fibrillation Market Share (%), By Company, 2025